Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1221-1230 of 1,460) with videos related to

Pageof 146
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2017
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenJesper Pallesen, Nianshuang Wang, Kizzmekia S Corbett, et al.
Vaccine|November 2, 2010
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood, P Costner, N Desai, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
Vaccine|June 9, 2020
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccinesPaul-Henri Lambert, Donna M Ambrosino, Svein R Andersen, et al.
Immunity|March 2, 2024
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidaseJulia Lederhofer, Yaroslav Tsybovsky, Lam Nguyen, et al.
American Journal of Epidemiology|September 21, 2000
Pooled analysis of prospective cohort studies on height, weight, and breast cancer riskP A van den Brandt, D Spiegelman, S S Yaun, et al.
Nature Communications|June 18, 2024
Epistasis mediates the evolution of the receptor binding mode in recent human H3N2 hemagglutininRuipeng Lei, Weiwen Liang, Wenhao O Ouyang, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Pageof 146

Showing results (1221-1230 of 1,460) with videos related to

Sort By:
Pageof 146
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2017
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenJesper Pallesen, Nianshuang Wang, Kizzmekia S Corbett, et al.
Vaccine|November 2, 2010
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood, P Costner, N Desai, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
Vaccine|June 9, 2020
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccinesPaul-Henri Lambert, Donna M Ambrosino, Svein R Andersen, et al.
Immunity|March 2, 2024
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidaseJulia Lederhofer, Yaroslav Tsybovsky, Lam Nguyen, et al.
American Journal of Epidemiology|September 21, 2000
Pooled analysis of prospective cohort studies on height, weight, and breast cancer riskP A van den Brandt, D Spiegelman, S S Yaun, et al.
Nature Communications|June 18, 2024
Epistasis mediates the evolution of the receptor binding mode in recent human H3N2 hemagglutininRuipeng Lei, Weiwen Liang, Wenhao O Ouyang, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Pageof 146